CDDP group versus 3.3 months in the IFN/FU group (p = 0.0048). Hematological toxicity was common, but no toxicity-related deaths were observed. Conclusion: These results show the clinical efficacy of adding CDDP to the hepatic arterial infusion of FU in combined chemotherapy regimens with IFN.
tion and percutaneous ethanol injection therapy, has progressed markedly, achieving a 5-year survival rate of 60-70% [5] . Most patients with HCC experience the repeated recurrence of tumors after treatment, and the disease may eventually reach an advanced stage. Furthermore, it is still not uncommon to find patients with symptomatic advanced HCC who have not participated in regular screening.
The efficacy of hepatectomy, local ablation therapy and transarterial chemoembolization (TACE) is limited for advanced HCC, and the prognosis of such cases is poor. Under these circumstances, systemic therapy with the molecular targeting drug sorafenib has shown a statistically significant survival benefit compared with placebo treatment in two large-scale phase III clinical trials [6, 7] . Based on these findings, this drug is now recommended as a standard treatment for advanced HCC. These trials did not compare sorafenib with other conventional treatments of advanced HCC but with best supportive care as the placebo treatment. Although a significant difference in the survival time was noted, the response rate was as low as 2-3.3%, with no significant difference from the results in the placebo arm (1-1.3%) [6, 7] .
As another optional treatment for advanced HCC, hepatic arterial infusion chemotherapy (HAIC) has been employed mainly in Japan and other Asian countries. HAIC has been used not only for unresectable HCC accompanied by vascular invasion but also uncontrollable cases of repeated recurrences within a short period of time despite a number of sessions of TACE.
In recent years, fluorouracil (FU) and cisplatin (CDDP) have been reported as the most commonly used anticancer drugs for HAIC [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Favorable results with an HAIC protocol using low-dose CDDP and FU have also been reported [8, 14, 16, 17] . Similarly, combination of interferon (IFN) with FU has demonstrated relatively good results in HAIC [11, 13, 18] .
With this background in mind and with the aim of establishing the most effective HAIC protocol for advanced HCC, we planned a phase II randomized clinical comparative study to examine whether or not IFN combined with HAIC consisting of FU and CDDP might be associated with a higher response rate. Patients with advanced HCC were randomly allocated to two treatment arms, i.e. IFN combined with hepatic arterial infusion of FU with CDDP or IFN combined with hepatic arterial infusion of FU alone without CDDP. The results were then compared with regard to the efficacy, safety and prognosis.
Patients and Methods

Patients
Patients who had histologically or clinically diagnosed HCC were included in this study. A clinical diagnosis of HCC was made based on underlying chronic liver disease, radiologic findings and elevation of tumor markers.
With regard to the tumor stage, the following patients were included: patients who had (1) severe vascular invasion (i.e. vascular invasion found in the main trunk to the secondary branches of the portal vein, or invasion in the right, middle or left hepatic vein) and (2) intrahepatic multiple lesions (i.e. 5 or more nodules in the left and/or right lobes as confirmed by radiology).
Patients were eligible when they were 20 years old or older, had an Eastern Clinical Oncology Group performance status of 2 or less and had appropriate bone marrow, liver, kidney and cardiac functions as determined by the following measurements obtained within 1 week before enrollment: hemoglobin 6 8.0 g/dl; white blood cell count 6 2,000/mm 3 ; platelet count 6 30,000/mm 3 ; blood urea nitrogen ^ 30 mg/dl; serum creatinine ^ 2.0 mg/dl; percentage of prothrombin time 6 30%, and total bilirubin ^ 5 mg/dl or less (excluding elevations caused by biliary tract obstruction as a result of HCC).
Assignment
The present study was an open randomized single-center study consisting of a two-group comparison. All the patients who satisfied the inclusion criteria were randomized to either of the two treatments. The treatment protocol was approved by the ethical committee of Kanazawa University (approval number 5169). Patients were given full information regarding the details of the clinical study and provided their written consent prior to participation in the study. This clinical study adhered to the Declaration of Helsinki and good clinical practice.
Treatment Schedule
A reservoir for hepatic arterial infusion was implanted prior to HAIC. A catheter with a side hole was inserted from the right femoral artery using an image-guided procedure, and the tip of the catheter was placed in the gastroduodenal artery or splenic artery. When more than one hepatic artery was present, the hepatic arteries were unified to the original proper hepatic artery alone. When blood flow into the gastrointestinal tract was confirmed by catheter angiography, the route was embolized to prevent complications. The reservoir was placed beneath the skin in the lower right abdomen. Medication was started at least 3 days after implantation.
In the IFN/FU treatment group, patients underwent continuous hepatic arterial infusion of FU (5-FU , Kyowa Hakko, Tokyo, Japan) at a dose of 300 mg/m 2 /day for 5 days in the 1st and 2nd weeks (for 120 h) using an infuser pump (Baxter Infusor SV1 , Tokyo, Japan) in the same manner as described in previous reports [18] . The maximum amount of FU infused over 5 days was 2,500 mg. IFN ␣ -2b (Intron A , Schering-Plough, Osaka, Japan) at a dose of 3,000,000 units was injected intramuscularly 3 times a week for 4 weeks. In the IFN/FU + CDDP treatment group, CDDP (Randa , Nippon Kayaku, Tokyo, Japan) at a dose of 20 mg/m 2 was given by hepatic arterial infusion over 1.5 h on days 1 and 8 prior to the administration of FU and after appropriate hy-dration and antiemetic medication. A treatment cycle comprised 4 weeks of drug administration including IFN administration and a subsequent 2-week rest period ( fig. 1 ).
Sample Size
Based on previous reports in the literature [9, 19] and the results of our studies of HAIC for the treatment of HCC using single-drug regimens, it was assumed that the response rate in the IFN/FU treatment group would be 20% and that in the IFN/FU + CDDP treatment group would be 50%. Based on the assumption that the ratio of the numbers of patients was 1: 1, the ␣ error was 0.05, the ␤ error was 0.1, and 52 patients were necessary for each treatment group. Therefore, the number of patients to be included was 114, allowing a 10% dropout rate, which would result in a total of 104 patients for the two groups.
Response Assessment
The primary endpoint was the response rate, as determined using dynamic computed tomography or magnetic resonance imaging performed at the end of each treatment cycle according to the Response Evaluation Criteria in Solid Tumors, version 1.0 [20] .
Secondary endpoints were the overall survival time, progression-free survival time and adverse events. The overall survival time was defined as the period from the time of randomization until death, and the progression-free survival time was defined as the period from the beginning of treatment until confirmation of progression or death. Adverse events were evaluated according to the Common Toxicity Criteria for Adverse Events, version 3.0.
Statistical Analyses
The two treatment groups were compared using the Fisher direct method and the Wilcoxon rank sum test. Response factors were analyzed using logistic regression analysis. The cumulative survival and prognostic factors were analyzed using the KaplanMeier method, log-rank test and the Cox proportional hazard regression model. 
Results
Patients
A total of 155 patients with advanced HCC were treated at our hospital between October 2003 and September 2007. Eventually, 114 patients were allocated to the IFN/ FU + CDDP treatment group or the IFN/FU treatment group. Three patients in the IFN/FU + CDDP group and 2 in the IFN/FU group dropped out before the end of the first cycle; therefore, a total of 109 patients, comprising 54 patients from the former group and 55 from the latter, were included in the efficacy evaluation ( fig. 2 ) .
The baseline clinical features of the 114 patients are shown in table 1 . No significant differences in the clinical features and test results were observed between the two groups, with the exception of a slightly higher bilirubin level in the IFN/FU group. The patients classified as having Barcelona Clinic Liver Cancer stage B had 5 or more nodules in the left and/or right lobes and were considered to have disease that was difficult to control by TACE after repeated TACE (68%) or multiple lesions that showed an inadequate response to TACE.
Response to Treatment
Among the 57 patients in the IFN/FU + CDDP treatment group, the best study response was a complete response (CR) in 1 (1.7%); partial response (PR) was observed in 25 (43.9%) patients, stable disease was observed The only factor that improved the response to treatment as indicated by a multivariate analysis was the addition of CDDP to the treatment [odds ratio 2.5, 95% confidence interval (CI) 1.1-6.0; table 3 ]. Table 4 shows the major adverse events. Grade 3 or 4 adverse events were found in 75 of the 114 patients (65.8%). Bone marrow suppression of any grade was found in 65-90% of the patients. Leukopenia and neutropenia were noted in about 70% of the patients, and no significant difference was found between the IFN/FU + CDDP group and the IFN/FU group. An overall reduction in hemoglobin was observed more frequently in the IFN/FU + CDDP group than in the IFN/FU group (91.2 vs. 75.4%; p = 0.021), although the difference was not significant for hemoglobin reductions of grade 3 or 4. No significant difference in all-grade thrombocytopenia was observed between the two groups, but thrombocytopenia of grade 3 or 4 was found significantly more frequently in the IFN/ FU + CDDP group (45.6 vs. 22.8%; p = 0.017). However, no serious complications secondary to a reduction in platelets occurred.
Safety
Nonhematologic toxicities including general malaise, nausea, vomiting, stomatitis and elevation of serum creatinine were significantly more common in the IFN/FU + CDDP group, but no intergroup difference was found for grade 3 or grade 4 toxicities.
Peptic ulcer arising from the leakage of arterially infused anticancer drugs into the gastrointestinal tract, a complication characteristic of HAIC, was found in 6 patients (10.5%) in the IFN/FU + CDDP group and 1 patient (1.8%) in the IFN/FU group; the incidence was higher, but not significantly, in the IFN/FU + CDDP group (p = 0.06), and no grade 3 or grade 4 cases occurred.
Survival
The median overall survival period of the 114 patients who underwent HAIC was 12.0 months (95% CI 11.6-12.4). In the IFN/FU + CDDP group, the median survival time (MST) was 17.6 months (95% CI 9.9-25.3). In the IFN/FU group, the MST was 10.5 months (95% CI 5.6-15.4). Although the survival period tended to be longer in the group given FU combined with CDDP, no statistically significant differences were observed between the two groups (p = 0.522, log-rank test; hazard ratio 0.88, 95% CI 0.60-1.30; fig. 3 a) .
In the subgroup with the presence of major vascular invasion, the MST was 5. The median overall progression-free survival period of the 114 patients was 4.5 months (95% CI 3.5-5.5). In the IFN/FU + CDDP group, the median progression-free survival time was 6.5 months (95% CI 2.6-10.4). In the IFN/FU group, the median progression-free survival fig. 3 b) .
As predictors for survival, a multivariate analysis showed that positivity for hepatitis C virus antibody (HCV-Ab), an albumin level of 3.5 g/dl or more and an aspartate aminotransferase (AST) value of lower than 80 IU/l were associated with improved survival ( table 5 ) .
Discussion
The present study showed that the addition of CDDP to IFN combined with HAIC using FU significantly enhanced the antitumor effect from 24.6 to 45.6%. The response rates obtained in previous studies of HAIC involving at least 30 patients varied from 14 to 71% [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Regarding the use of IFN combined with HAIC using FU, Obi et al. [13] used this treatment in patients with advanced HCC and a tumor embolus in the main trunk or the first branch of the portal vein and achieved a response rate of 52.6%. Ota et al. [18] also used IFN combined with HAIC using FU for similar cases of advanced HCC and reported a response rate of 43.6%. We previously reported a response rate of 45% in 34 patients who underwent multidrug HAIC using FU and CDDP in combination with IFN treatment [11] . Uka et al. [21] used IFN in combination with HAIC using FU in 55 patients who had a tumor embolus of the portal vein and reported a response rate of 29%. The response rates obtained in the present study were similar to those obtained in the report by Uka et al. [21] and lower than those obtained in the other two reports. This discrepancy may be explained by the different criteria used to evaluate antitumor efficacy, as Uka et al. [21] suggested in their discussion. Obi et al. [13] and Ota et al. [18] used the Eastern Clinical Oncology Group criteria, whereas Uka et al. [21] and the present study used the Response Evaluation Criteria in Solid Tumors.
The combined use of FU and IFN is reportedly beneficial because IFN serves as a modulator to enhance the antitumor effect of FU. More specifically, IFN induces p53, which enhances apoptosis by FU, and influences the cell cycle via p27
Kip1 or apoptosis via Bcl-xL [22, 23] . From a clinical perspective, Takaki-Hamade et al. [24] and Eun et al. [25] concluded that combined IFN treatment did not have an incremental effect. Thus, the benefit of adding IFN to HAIC with FU has not been proven clinically. However, experimental data suggest that IFN should enhance the antitumor effect of FU [22, 26] , and this supports the current use of IFN-combined HAIC in clinical practice.
On the other hand, with regard to the effect of CDDP combined with FU in a clinical setting, Ando et al. [8] used HAIC with FU combined with low-dose CDDP for the treatment of patients with advanced HCC and a portal tumor embolus and reported a response rate of 48%. Following their report, several other reports on HAIC with FU combined with low-dose CDDP were published, with reported response rates ranging from 38.5 to 71% [14, 16, 17, 27] . Experimental studies have shown that low-dose CDDP blocks methionine transport into the cell, causing a decrease in intracellular methionine and an increase in reduced folic acid, thus serving as a modulator of FU to enhance its antitumor efficacy [28] . It has also been reported that low-dose CDDP is involved in the inhibition of p53-mediated apoptosis and drug resistance [29] . The present study used two agents, IFN and CDDP, in combination with FU. Although IFN and CDDP seem to enhance the antitumor effect of FU through these pathways, a large amount of basic experimental research on FU combined with these two agents remains to be performed.
Our present study showed that the antitumor effect was significantly greater and the progression-free survival time was significantly longer in the IFN/FU + CDDP group. However, there was no statistically significant difference in the overall survival time. Subgroup analysis also did not show survival benefit in the IFN + CDDP group. Since there were no limitations on treatment after the end of the protocol treatment, 88 of the 114 patients (77.2%) underwent some treatment subsequently, and 34 patients (59.6%) in the IFN/FU group received HAIC (mainly IFN/FU + CDDP) eventually. This might have had some effects on the results for overall survival.
The factors that improved survival in this study included positivity for HCV-Ab, an albumin level of 3.5 g/dl or more and an AST value of lower than 80 IU/l. Previous reports have documented the presence of response to chemotherapy, the Cancer of the Liver Italian Program score, the Okuda stage, the Child-Pugh score and ␣ -fetoprotein as prognostic factors for HAIC in advanced HCC [30, 31] . Obi et al. [13] also reported that positivity for HCV-Ab was a predictor of a CR to IFN combined with HAIC using FU. Uka et al. [21] reported that positivity for HCV-Ab was a factor associated with the early antitumor effect, progression-free time and overall survival after IFN combined with HAIC. Thus, positivity for HCVAb was determined to be a factor that improved prognosis. A possible explanation for this discrepancy may be that viral differences between hepatitis B virus and HCV may be involved in the heterogeneity of the anticancer drug sensitivity of HCC, or differences in the cytokine patterns of hepatitis B virus and HCV infections may influence the effect of IFN [32] [33] [34] [35] . However, the true explanation remains unclear. In connection with an AST value of lower than 80 IU/l, Cheong et al. [36] also reported that low levels of AST and alkaline phosphatase were associated with long-term survival exceeding 8 months in a study examining chemotherapy including HAIC for the treatment of patients with advanced HCC. The basis of their findings requires further investigation. Most patients with HCC have concomitant hepatic cirrhosis and thus have pancytopenia. Therefore, with regard to adverse events, we expected to see enhanced blood toxicity when IFN and CDDP were added to FU. Thus, this study showed a significantly higher frequency of cytopenia in the IFN/FU + CDDP group. However, as far as severe hematologic toxicities of grade 3 or 4 were concerned, thrombocytopenia alone was significantly more frequent in the IFN/FU + CDDP group, but no complications secondary to thrombocytopenia occurred. Although some nonhematologic toxicities were significantly more frequent in the IFN/FU + CDDP group, these adverse events were controllable. Thus, IFN combined with HAIC using FU and CDDP seems to be tolerable with regard to the occurrence of adverse events. The frequency of grade 3 or 4 toxicity with IFN-combined HAIC in our study was higher than that with sorafenib therapy reported previously [6, 7] . We enrolled 45 patients (39.5%) in Child-Pugh class B, and the pretreatment blood cell count in patients of Child-Pugh class B was generally lower than that of those patients in Child-Pugh class A. In addition, IFN has the effect of decreasing the blood cell count, especially neutrophils and platelets. However, these toxicities were controllable and there were no toxicity-related deaths.
In conclusion, the results of this phase II randomized clinical study on the effect of adding CDDP to IFN in combination with HAIC using FU for the treatment of advanced HCC show that the addition of CDDP significantly increases the antitumor effect of the treatment and results in a significant improvement in the progressionfree survival time. Although there was no significant difference in the overall survival time of the two treatment groups, the survival benefit of IFN combined with HAIC using CDDP should be examined in comparison with systemic therapy using sorafenib, the current standard treatment for advanced HCC. In this regard, a multicenter study of hepatic arterial infusion of FU versus sorafenib therapy is now under way in Japan, and the results are awaited.
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